Breast Cancer Screening, Risk Factors, and Treatment Options
This paper examines breast cancer as the second leading cause of cancer death among American women, focusing on U.S. Preventive Services Task Force mammography screening recommendations. It analyzes how genetic factors—particularly BRCA1/2 mutations—and ethnic disparities influence decisions about preventive services. The paper then describes key drug treatment options, including chemotherapy agents, hormonal therapy (notably tamoxifen), and HER2-targeted therapies such as trastuzumab. Finally, it outlines the short-term and long-term implications of each treatment category, covering side effects ranging from manageable fatigue and hair loss to rare but serious outcomes such as heart damage and secondary cancer.
- Breast Cancer Screening Guidelines: USPSTF mammography recommendations by age group
- Genetic Factors and Preventive Decision-Making: BRCA1/2 mutations and high-risk screening protocols
- Ethnic Factors and Preventive Decision-Making: Disparities in cancer screening among minority populations
- Drug Treatment Options for Breast Cancer: Chemotherapy, hormonal therapy, and HER2-targeted drugs
- Short-Term and Long-Term Implications of Treatment: Side effect profiles across all three treatment categories
- References: Cited sources and bibliography
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Anchors each section in specific statistics and clinical data, giving concrete grounding to policy and treatment claims (e.g., median mortality age, BRCA1/2 carrier rates, trastuzumab heart-risk percentages).
- Moves logically from population-level screening guidance to individual risk factors to treatment options and their consequences, creating a coherent clinical narrative.
- Balances biological and sociocultural dimensions of cancer care by pairing the genetic risk section with an ethnic disparities section, demonstrating multi-factor awareness.
Key academic technique demonstrated
The paper consistently distinguishes between categories of evidence—screening task force recommendations, epidemiological research, and clinical pharmacology—and assigns each claim to an appropriate source. This source-matched argumentation, where a regulatory recommendation cites the USPSTF, a sociocultural claim cites Bamidele et al., and drug efficacy claims cite Cancer.Net or the National Cancer Institute, shows disciplined use of authoritative, domain-specific references rather than relying on a single general source.
Structure breakdown
The paper opens with an epidemiological overview and screening guidelines, then addresses two categories of factors influencing preventive decisions (genetic and ethnic), followed by a pharmacological survey of treatment types (chemotherapy, hormonal therapy, HER2-targeted therapy), and closes with a discussion of treatment side effects across short- and long-term horizons. Each section is self-contained but builds on the prior one, moving from prevention to diagnosis to treatment to outcomes.
Breast Cancer Screening Guidelines
Breast cancer is the second leading cause of cancer death among American women. In 2015, roughly 232,000 women—most between 55 and 64 years of age—received positive cancer diagnoses, and 40,000 succumbed to the disease. The median age of breast cancer-related mortality is 68 years. The U.S. Preventive Services Task Force (USPSTF) advises all women aged 50 to 74 to undergo screening mammography once every two years. Women may individually decide to begin screening mammography before age fifty. Those who place greater value on the potential benefits of screening over its disadvantages may opt for biennial screening starting at age forty.
For women displaying average breast cancer risk, most of the benefits linked to mammography will result from two-yearly screening between ages 50 and 74. Of all age groups, women aged 60 to 69 display the greatest likelihood of avoiding death due to breast cancer through mammography screening (U.S. Preventive Services Task Force, 2016).
Genetic Factors and Preventive Decision-Making
High-risk women include those with a family history of cancer sufficient to elevate calculated lifetime cancer development probability above the 20–25% benchmark, as well as those with a known high-risk genetic mutation. Preliminary population screening studies and research on individuals with breast cancer indicate that 10 to 15 percent of women with a significant family history are likely BRCA1/2 mutation carriers, with roughly 50% unaware of their carrier status. Screening is recommended for such individuals, along with genetic testing and counseling, risk-reduction surgery, chemoprevention counseling, and increased surveillance options when an individual meets genetic or familial risk criteria (Padamsee, Wills, Yee & Paskett, 2017).
Create your account
Always verify citation format against your institution’s current style guide requirements.